Last reviewed · How we verify
Locally advanced or metastatic esophageal squamous cell carcinoma — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Disitamab vedotin | disitamab-vedotin | Pfizer | antibody-drug conjugate | human epidermal growth factor receptor 2 (HER2) |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Locally advanced or metastatic esophageal squamous cell carcinoma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Locally advanced or metastatic esophageal squamous cell carcinoma:
- Locally advanced or metastatic esophageal squamous cell carcinoma treatment updates — RSS
- Locally advanced or metastatic esophageal squamous cell carcinoma treatment updates — Atom
- Locally advanced or metastatic esophageal squamous cell carcinoma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Locally advanced or metastatic esophageal squamous cell carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/locally-advanced-or-metastatic-esophageal-squamous-cell-carcinoma. Accessed 2026-06-10.
Related
- Locally advanced or metastatic esophageal squamous cell carcinoma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing